NCT04423367

Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment

Safety and Efficacy of Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment: A Prospective Phase II Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, single-arm study to evaluate the safety and efficacy of bortezomib plus dexamethasone for acquired pure red cell aplasia failure or relapse after first-line treatment.

Conditions

• Acquired Pure Red Cell Aplasia

Interventions

Type	Name	Description
DRUG	bortezomib/dexamethasone	Enrolled patients would receive the combination therapy of bortezomib and dexamethasone.

Timeline

• Start date: 2020-09-13
• Primary completion: 2024-07-31
• Completion: 2024-09-30
• First posted: 2020-06-09
• Last updated: 2026-02-11

Locations

3 sites across 1 country: China